Skip to main content
Premium Trial:

Request an Annual Quote

Pairings: Feb 18, 2009

Premium

Alan Carter will serve as Agendia's new VP of global business development. Carter formerly served as an executive at BioTrove, Celera, Applied Biosystems, and PerkinElmer.


Pfizer announced the appointment of David Cox as the chief scientific officer of its Target Generation Unit. Cox was a co-founder of Perlegen, and chief scientific officer at the company since its inception in 2000. He was also professor of genetics and pediatrics at the Stanford University School of Medicine as well as the co-director of the Stanford Genome Center.


John Alsobrook has been promoted to vice president and chief operating officer of Exagen Diagnostics. In his new role, Alsobrook will report to Exagen Founder and Interim CEO Waneta Tuttle.

Prior to his new position, Alsobrook was a consultant for Genaissance Pharmaceuticals, Amersham Health, GE Healthcare, and Massachusetts General Hospital. Alsobrook also worked at CuraGen as genetics supervisor for drug discovery and as senior research scientist for pharmacogenomics. From 1996 to 2000, Alsobrook was an associate faculty scientist at Yale School of Medicine Child Study Center, where he investigated inherited psychiatric disorders.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.